Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP shares passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $8.05 and traded as low as $7.45. Aurinia Pharmaceuticals shares last traded at $7.59, with a volume of 1,404,253 shares traded.
Analysts Set New Price Targets
Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.
Read Our Latest Stock Analysis on AUPH
Aurinia Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.26 and a current ratio of 5.93. The business has a 50-day moving average price of $8.04 and a 200 day moving average price of $8.08. The stock has a market capitalization of $1.19 billion, a P/E ratio of 31.43 and a beta of 1.16.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. Aurinia Pharmaceuticals had a net margin of 16.11% and a return on equity of 14.27%. The company had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. As a group, sell-side analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.
Hedge Funds Weigh In On Aurinia Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in AUPH. Nuveen LLC purchased a new position in Aurinia Pharmaceuticals in the 1st quarter worth approximately $10,014,000. Tang Capital Management LLC raised its stake in Aurinia Pharmaceuticals by 16.6% during the 4th quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock valued at $75,697,000 after buying an additional 1,200,000 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $9,662,000. Point72 Asset Management L.P. purchased a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $7,630,000. Finally, Jupiter Asset Management Ltd. purchased a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at $6,052,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
